LGS Foundation Launches Global Initiative for Awareness Day 2025

The Lennox-Gastaut Syndrome (LGS) Foundation has announced the return of the International LGS Awareness Day on November 1, 2025, coinciding with the start of Epilepsy Awareness Month. This annual event aims to amplify global awareness about LGS, a severe form of epilepsy, and to drive essential research funding and innovation. The Foundation is calling on patients, healthcare providers, and researchers to unite in raising awareness and supporting families impacted by this condition.

“Every day, families affected by LGS fight battles most of the world never sees,” stated Dr. Tracy Dixon-Salazar, Executive Director of the LGS Foundation. “International LGS Awareness Day is more than an awareness event—it’s a global call to action to fuel discovery, drive research, and ensure that every person living with LGS has a chance at a better tomorrow.”

Understanding LGS and Its Global Impact

Lennox-Gastaut Syndrome is characterized by treatment-resistant seizures, cognitive impairment, and significant behavioral challenges, impacting over one million children and adults worldwide. Despite its prevalence, LGS remains under-recognized and underfunded compared to other neurological conditions, such as Cystic Fibrosis and Lou Gehrig’s Disease. This lack of awareness results in substantial unmet medical needs for patients and their families.

The Foundation’s campaign, running from October 13 to November 23, 2025, includes the International LGS Awareness Day and initiatives like the Illuminate for LGS project, which will light up landmarks around the world to raise visibility for the condition. Additionally, a multi-day online silent auction will be held to support research funding.

Engaging Communities and Supporting Research

To enhance participation, the LGS Foundation encourages organizations and individuals to utilize various awareness tools. These include the “Together for a Breakthrough” apparel and yard signs designed to stimulate conversation and visibility. Digital content and awareness graphics will also be available for sharing on social media platforms.

Moreover, the Foundation emphasizes the importance of hosting events or initiating peer-to-peer fundraising campaigns to inspire local community actions. The LGS Foundation supports numerous research initiatives, including the LGS Learn From Every Patient Database and the Cure LGS 365 Research Grants, which aim to uncover disease mechanisms and improve treatment options.

To maximize the impact of this initiative, the Foundation is actively seeking corporate and industry partnerships. Collaborations at various levels can enhance visibility and support for awareness, research, and family resources.

LGS, as one of the most common rare epilepsies, presents significant medical challenges and poor outcomes for those affected. Raising awareness among biotech and pharmaceutical companies, alongside patients and families, represents a vital opportunity to address these challenges. Stakeholders involved in this initiative can help reshape the research agenda, foster earlier diagnosis, and ultimately improve therapeutic options for patients.

The LGS Foundation is dedicated to improving the lives of individuals impacted by Lennox-Gastaut Syndrome through advancing research, awareness, education, and family support. For more information or to get involved, visit www.lgsfoundation.org.